Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia

We assessed minimal residual disease (MRD) detection and B-cell aplasia after tisagenlecleucel therapy for acute lymphoblastic leukemia (ALL) to define biomarkers predictive of relapse (N = 143). Next-generation sequencing (NGS) MRD detection >0 in bone marrow (BM) was highly associated with rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Pulsipher, Michael A., Han, Xia, Maude, Shannon L., Laetsch, Theodore W., Qayed, Muna, Rives, Susana, Boyer, Michael W., Hiramatsu, Hidefumi, Yanik, Gregory A., Driscoll, Tim, Myers, G. Doug, Bader, Peter, Baruchel, Andre, Buechner, Jochen, Stefanski, Heather E., Kalfoglou, Creton, Nguyen, Kevin, Waldron, Edward R., Thudium Mueller, Karen, Maier, Harald J., Kari, Gabor, Grupp, Stephan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9924295/
https://www.ncbi.nlm.nih.gov/pubmed/35019853
http://dx.doi.org/10.1158/2643-3230.BCD-21-0095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9924295/
https://www.ncbi.nlm.nih.gov/pubmed/35019853
http://dx.doi.org/10.1158/2643-3230.BCD-21-0095

Ejemplares similares